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Study objectives: To determine the relationship between pulmonary arterial systolic pressure (PASP) and submaximum capacity of exercise,
using the six-minute walk test (6MWT) in patients with cystic fibrosis (CF), and to investigate the relation between echocardiographic
findings and results of 6MWT, clinical scores, chest radiograph scores and lung function tests.
Design: This was a prospective cross-sectional study in patients with CF (16 years and older) with clinical stability, attending the Adult CF
Program at the Hospital de Clínicas de Porto Alegre. The patients had Doppler echocardiography and performed a 6MWT. As well as
pulmonary function tests and chest roentgenograms, and a clinical score was obtained for all patients.
Results: The study included 39 patients with a mean age of 23.7±6.3 years. There were no significant correlation between the distance
walked and PASP, diameter of the right ventricle (DRV) and pulmonary acceleration time ( pN0.05). We observed a significant correlation
among PASP and the SpO2 at rest (r=−0.73; pb0.001), SpO2 at the end of the 6MWT (r=−0.45; p=0.006), clinical score (r=−0.55;
p=0.001), chest radiograph score (r=−0.33; p=0.049), FEV1 (r=−0.63; pb 0.001), and FVC (r=−0.55; p=0.001). Right ventricular
outflow tract flow acceleration time (Ac T) was significantly correlated only with the FEV1 (r=0.32; p=0.047). RVD was significantly
correlated with SpO2 at rest (r=−0.44; p=0.005) and clinical score (r=−0.38; p=0.017). The SpO2 at rest was the single best predictor of
PASP and this effect was independent of the relationship between other independent variables ( p=0.001). The declining pulmonary function
was significantly associated with PASP ( pb0.001), SpO2 at rest ( p=0.001), SpO2 at the end of the 6MWT ( p=0.007) and difference
between peripheral oxygen saturation at resting and at the end of the 6MWT ( p=0.025).
Conclusion: The PASP was not significantly correlated with the distance walked during the 6MWT in patients with CF. The PASP was
strongly correlated with oxygen status at rest. The SpO2 at rest was the best predictor of PASP. Also, PASP was strongly correlated with
Shwachman–Kulczycki score, FEV1, and FVC in this population.
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In patients with cystic fibrosis (CF), continuous pulmo-
nary infection and inflammation with thickened secretions
cause airways obstruction and hyperinflation. [1] As the
disease progresses, these patients develop disabling lunged by Elsevier B.V. All rights reserved.
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hypertension (PH) [2].
PH is considered to be a consequence of several
mechanisms that either raise the pressure downstream of
the pulmonary capillaries, induce vasoconstriction, increase
blood flow to the lung, or obstruct the pulmonary vessels
either by embolism or in situ fibrosis. The pathophysiology
of PH and cor pulmonale in CF is thought to be related to
progressive destruction of the lung parenchyma and
pulmonary vasculature, and to pulmonary vasoconstriction
secondary to hypoxemia [3,4].
The echocardiogram is an integral part of the evaluation
of a patient with PH. Common echocardiographic findings in
PH includes right atrial and right ventricular (RV) enlarge-
ment, reduced RV function, displacement of the intraven-
tricular septum to the left, and tricuspid regurgitation that
permits the estimation of the pulmonary artery systolic
pressure (PASP) [5–7]. In CF, as in other lung diseases,
desaturation is accentuated during exercise [8]. Episodic
hypoxemia and hypercapnia may occur during times of
physiologic stress in CF, namely exercise. It has been
proposed that during exercise moderate hypoxemia and
hypercapnia occur because of wasted ventilation and
expiratory flow limitation. It has also been proposed that
exercise limitation in CF is greatest in those with diminished
nutritional status [9].
The ability to walk for a distance is a quick and
inexpensive measure of physical function, and an important
component of quality of life since it reflects the capacity to
undertake day-to-day activities [10].
The six-minute walk test is a submaximal exercise test
that can be performed by a patient intolerant of maximal
exercise tests. The test is very simple, requires inexpensive
equipment, and is reproducible. In addition, it is considered
safe because patients are self-limited during exercise.
Recently the distance walked in 6 min has been shown to
correlate significantly with maximal oxygen uptake [11].
The objectives of this study were (1) to assess the relation
between PASP and the distance walked during the six-
minute walk test (6MWT) in patients with CF, (2) to
determine the relation between PASP and exercise induced
hypoxemia by using the 6MWT, and (3) to investigate the
relation between echocardiographic findings and results of
6MWT clinical scores (Shwachman–Kulczycki) [12], chest
radiograph scores (Brasfield) [13] and lung function tests.
2. Materials and methods
2.1. Patient population
CF patients (z16 years old) confirmed by an abnormal
sweat test result were recruited from the Adult CF Program at
Hospital de Clínicas de Porto Alegre (HCPA). We recruited
14 patients with severe lung disease (FEV1b40% of the
predicted normal value), 12 patients with moderately severe
lung disease (FEV1 40 to 65% predicted), and 13 patientswith mild lung disease (FEV1N65% predicted). All patients
were in clinically stable condition. Patients were excluded if
they had a known primary cardiac disease (such as
congenital heart disease, rheumatic valve disease, or
pericarditis), if they had received domiciliary oxygen
therapy, or if they were pregnant.
2.2. Study design
This was a single-center, prospective cross-sectional
study in which all patients attending the Adult CF Program
at HCPAwho volunteered for the study were included. Each
CF patient had a comprehensive evaluation of their health
status with the assessment of clinical stability by a senior
member of the research team. In the same week a Doppler
echocardiographic study, a pulmonary function test, a chest-
x ray, and a 6MWT were performed with all patients. The
protocol was approved by the HCPA Ethics Committee and
informed consent was obtained from each patient.
2.3. Six-minute walk test
The distance the patient was able to walk in 6 min was
determined using a corridor of 30 m long, following a
standardized protocol [14]. The patients were instructed to
walk as far as possible for 6 min under the supervision of a
physiotherapist. Technicians encouraged subjects with the
standardized statements, “You are doing well” or “Keep up
the good work,” but were asked not to use other phrases [14].
The total distance walked and the initial and final SpO2 were
recorded by pulse oximetry (NPB-40; Nellcor Puritan
Bennett; Pleasanton; USA). Two tests were done and the
best result was reported. All patients tolerated the six-minute
walk test without any adverse effects.
2.4. Echo-Doppler studies
M-mode, two-dimensional, and Doppler echocardiogra-
phy (ATL-HDI 5000; Washington; USA) were performed
from the standard parasternal, apical, and subcostal views in
the resting state, in the semisupine, left lateral position, by the
same observer blinded to the clinical status of the patients.
PASP was measured from the continuous-wave Doppler
signal of the tricuspid regurgitation gradient by the
simplified Bernoulli equation (Dp=4v2, where Dp is the
peak pressure difference between right ventricular and right
atrium, and v is the peak flow velocity of the tricuspid
regurgitant jet) and added to the right atrial pressure, which
was assumed to be 10 mm Hg. PASP was considered
elevated when greater than 35 mm Hg [15]. From the
pulmonary forward flow trace, the pulmonary acceleration
time (Ac T) was calculated as the time interval between the
onset of flow and the peak flow velocity. The right
ventricular dimension was measured at end diastole from
M-mode traces and by using the recommendations of the
American Society of Echocardiography [16].
Table 1
Characteristics of patients according values of the PASP
Variable PASPb35 mm Hg (n=16) PASP≥35 mm Hg (n=23) RR CI 95% p value
Age (years) 21.4±4.7 25.2±6.8 1.01 1.00–1.02 0.065
Age at diagnosis (years) 11.0±9.4 11.6±11.8 1.00 0.99–1.00 0.865
Sex (male/female) 5/11 13/10 1.52 0.89–2.58 0.258
BMI (kg/m2) 20.3±2.4 20.7±2.5 1.00 0.97–1.04 0.641
S–K clincal score 84.3±10.3 71.5±11.0 0.98 0.98–0.99 0.001
Brasfield score 18.3±3.2 14.8±3.9 0.96 0.94–0.98 0.007
FEV1 (% predicted) 71.9±28.5 44.3±19.8 0.99 0.98–0.99 0.001
FVC (% predicted) 78.8±21.3 60.3±19.8 0.99 0.98–0.99 0.009
Physical activity (% of yes) 41% 59% 1.19 0.61–1.75 0.894
6MWT
Distance (m) 560.1±88.7 559.7±69.9 0.99 0.99–1.00 0.988
SpO2 at rest (%) 98.0±0.8 95.8±1.8 0.91 0.87–0.94 b 0.001
SpO2 at the end (%) 96.7±2.0 92.4±6.6 0.98 0.96–0.99 0.017
ΔSpO2 (%) 1.3±2.2 3.7±5.3 1.01 1.00–1.02 0.101
HR at rest (bpm) 84.8±11.68 86.0±12.6 1.00 0.99–1.00 0.771
HR at end (bpm) 123.6±21.4 123.7±21.5 0.99 0.99–1.00 0.900
Data are presented as the mean±SD.
PASP=pulmonary artery systolic pressure; BMI=body mass index; S–K=Schwachman–Kulczycki; FEV1=forced expiratory volume in the first second;
FVC=forced vital capacity; 6MWT=six-minute walk test; SpO2=peripheral oxygen saturation; ΔSpO2=difference between peripheral oxygen saturation at
resting and in the end 6MWT; HR=heart rate.
Student's t test for continuos variables and chi-square test for categorical variables.
Table 2
Correlation between echocardiographic findings and results of 6MWT,
clinical scores (Shwachman–Kulczycki), chest radiographs scores
(Brasfield) and lung function tests
Variable PASP Ac T RVD
Walk distance r=−0.25 r=0.10 r=0.15
p=0.141 p=0.564 p=0.362
SpO2 at rest r=−0.73 r=0.06 r=−0.44
pb0.001 p=0.702 p=0.005
SpO2 at end 6MWT r=−0.45 r=0.26 r=−0.24
p=0.006 p=0.112 p=0.136
S–K clinical score r=−0.54 r=0.30 r=−0.38
p=0.001 p=0.067 p=0.017
Brasfield score r=−0.33 r=0.27 r=−0.31
p=0.049 p=0.107 p=0.054
FEV1 (% predicted) r=−0.63 r=0.32 r=−0.31
pb0.001 p=0.047 p=0.053
FVC (% predicted) r=−0.55 r=0.30 r=−0.21
p=0.001 p=0.064 p=0.190
PASP=pulmonary artery systolic pressure; Ac T=Right ventricular outflow
tract flow acceleration time; RVD=right ventricle dimension; 6MWT=six-
minute walk test; S–K=Schwachman–Kulczycki; SpO2=peripheral oxy-
gen saturation; FEV1=forced expiratory volume in the first second;
FVC=forced vital capacity; r=Pearson correlation coefficient. Pearson
linear correlation.
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The clinical score was performed by the same senior
member of the CF team in the out-patient setting, using the
Shwachman–Kulczycki scoring system [12].
All chest roentgenograms of CF patients were scored
using the Brasfield scoring system [13] by the same senior
member of the research team. This observer was blinded to
the clinical severity status of the patients.
2.6. Pulmonary function tests
Spirometry was measured with computerized spirometer
(Jaeger — v 4.31; Wuerzburg; Germany). FVC, FEV1 and
FEV1/FVC were measured three times, and the best result
was reported. All parameters were expressed as percent
predicted for age, stature, and gender [17].
2.7. Statistical analysis
Data are expressed as proportion or mean±standard
deviation (SD). Student's t test was used for comparison
between groups with PASP b35 mm Hg and with PASP
≥35mmHg.Categorical comparisonswere performed by chi-
square test. Relative risk was calculated for the characteristics
of patients classified according values of the PASP greater or
equal to 35 mm Hg. Correlations were determined using
Pearson linear correlation. Stepwise forward linear (method
enter) was performed for independent variables associated
significantly with PASP. Sensitivity, specificity and predictive
values were calculated for different cutoffs of a SpO2 at rest to
predict PASP of 35 mm Hg or greater. Data from the three
groups of lung function were evaluated with a one-wayanalysis of variance and a pos-hoc test multiple comparisons
(Tukey test) was performed. Data analysis was carried out
using the SPSS software package, version 13.0 and Stata
statistical software (Stata, College Station, TX). The statistical
significance level was set at pb0.05. All probabilities reported
were two-tailed. We calculated the sample size, using a
correlation coefficient of r=0.5 between the PASP and the
distance walked in 6MWT noted in the first 5 CF patients. An
Fig. 2. Correlation between PASP and peripheral oxygen saturation at rest.
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least 38 subjects∝=0.05 and 1−β=90%.
3. Results
Thirty-nine of 41 patients attending the Adult CF
Program at HCPA were included in the study. One patient
refused to participate in the study. Another patient was
excluded from the study because she was receiving
domiciliary oxygen therapy. The mean age of our patients
was 23.7±6.3 years (range from 16 to 47). There were 21
female and 18 male patients. All patients were Caucasian.
The mean body mass index was 20.5±2.5 kg/m2 (range form
16.5 to 28.1). During the 6MWT test, subjects walked a
mean distance of 559.9±77.1 m (range from 420 to 714).
The right ventricular outflow tract flow acceleration time
Ac T could not be obtained in one patient because
hyperinflation of the chest limited visualization of the
Doppler signal of tricuspid regurgitation. In three patients the
tricuspid regurgitation gradient could not be determined and
consequently the PASP could not be determined. These
patients were analyzed in the group with normal PASP.
Table 1 summarizes the characteristics of patients
according values of the PASP found in our patients. PASP
was greater than 35 mm Hg in 23 patients. This group
presented decreased values of clinical score, chest radio-
graph score, FEV1 % predicted, FCV % predicted, and
peripheral oxygen saturation at rest and at the end of the
6MWT significantly compared to normal PASP ( pb0.05).
Pearson linear correlation analysis (Table 2) showed that
PASP was not significantly correlated with the distance
walked in 6 min (r=−0.25; p=0.141, Fig. 1). The PASP was
significantly correlated with SpO2 at rest (r=−0.73;
pb0.001, Fig. 2), SpO2 at the end of the 6MWT (r=
−0.45; p=0.006), clinical score (r=−0.55; p=0.001), chest
radiograph score (r=−0.33; p=0.049), FEV1 (r=−0.63;
pb0.001), FVC (r=−0.55; p=0.001). The Ac T wasFig. 1. Correlation between PASP and the distance walked on 6MWT.significantly correlated only with the FEV1 (r=0.32;
p=0.047). RVD was significantly correlated with SpO2 at
rest (r=−0.44; p=0.005) and clinical score (r=−0.38;
p=0.017). In the stepwise forward linear (method enter) we
observed (Table 3) that SpO2 at rest was the single best
variable associated with PASP and that this effect was
independent of the relationship between other independent
variables ( p=0.001).
We calculated sensitivity, specificity and predictive values
for different cutoffs of a SpO2 at rest to predict PASP of
35 mm Hg or greater. For a cutoff of 96% or less in SpO2 at
rest we found a sensitivity of 56%, a specificity of 100%, a
positive predictive value of 100% and a negative predictive
value of 62,9%.
Pearson linear correlation analysis showed that BMI was
not significantly correlated with the distance walked in
6MWT (r=0.17; p=0.290), PASP (r=0.01; p=0.938), Ac T
(−0.06; p=0.735) and RVD (r=0.14; p=0.404).
Characteristics of patients according lung function are
summarized in Table 4. Declining pulmonary function was
significantly associated with PASP ( pb0.001), SpO2 at rest
( p=0.001), SpO2 at the end of the 6MWT ( p=0.007) andTable 3
Linear regression analysis for variables associated with PASP
Variable B Beta 95% CI p value
Sex 1.57 0.12 −2.10–5.25 0.387
Age (years) −0.04 −0.04 −0.35–0.27 0.787
S–K clinical score −0.11 −0.20 −0.34–0.13 0.354
Brasfield score 0.22 −0.13 −0.34–0.77 0.429
FEV1 (% predicted) −0.05 −0.18 −0.18–0.08 0.462
SpO2 at rest (%) −2.62 −0.74 −4.08–−1.17 0.001
SpO2 at end 6MWT(%) 0.19 0.16 −0.21–0.59 0.334
PASP=pulmonary artery systolic pressure; S–K=Schwachman–Kulczycki;
FEV1=forced expiratory volume in the first second; SpO2=peripheral
oxygen saturation; 6MWT=six-minute walk test; B=coefficient angular.
Linear regression analysis (method enter).
Table 4
Characteristics of patients according with lung function
Patients characteristics Mild lung disease (n=13) Moderate lung disease (n=12) Severe lung disease (n=14) p value
Age (years) 20.5±4.9 25.0±5.5 25.5±7.3 0.075
Sex (male/female) 4/9 7/5 7/7 0.354
PASP 29.3±4.5A 38.0±3.7B 39.8±6.5B b0.001
FEV1 (% predicted) 89.1±15.1
A 48.8±8.0B 30.5±7.1C b0.001
FVC (% predicted) 93.3±11.8A 64.5±11.0B 47.22±9.2C b0.001
Distance 6MWT(m) 589.1±92.3 564.3±53.1 529.0±72.1 0.124
SpO2 at rest (%) 98.1±1.1
A 96.3±1.1B 95.8±2.1B 0.001
SpO2 at the end 6MWT(%) 97.3±2.0
A 94.8±3.0AB 90.8±7.7B 0.007
ΔSpO2 (%) 0.92±2.2
A 1.7±1.8AB 5.2±6.4B 0.025
Data are presented as the mean±SD.
PASP=pulmonary artery systolic pressure; FEV1=forced expiratory volume in the first second; FVC=forced vital capacity; 6MWT=six-minute walk test;
SpO2=peripheral oxygen saturation; ΔSpO2=difference between peripheral oxygen saturation at resting and in the end 6MWT.
Analysis-of-variance for continuous variables and chi-square test for categorical variables and pos-hoc test (Tukey test): means significantly different if different
letters; AB does not differ from A or B.
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and at the end of the 6MWT ( p=0.025).
4. Discussion
In this study, we found no significant correlation between
the PASP and the distance walked during the 6MWT in
patients with CF. Twenty-three of 39 (59%) patients
presented PASP≥35 mm Hg. The mean distance walked
during the 6MWT in patients with PASP≥35 mm Hg was
559.7±69.9 m, and in patients with PASPb35 mm Hg it was
560.1±88.7 m. Our findings are consistent with a previous
report by Miyamoto et al. [11], who demonstrated in patients
with primary pulmonary hypertension (PPH) that the
distance walked in 6MWT was not significantly correlated
with mean pulmonary arterial pressure. In our study, one
possible reason for this finding was that every patient studied
was young, with a mean age of 23.7 years, in stable con-
dition, and carrying on with normal daily living activities.
Although no correlation with PASP was demonstrated,
the distance walked in 6MWTcan provide an assessment of a
different clinical dimension in patients with respiratory
disability. The 6MWT is a simple and non-expensive test that
can provide a global evaluation of exercise capacity and the
distance walked is the most important outcome measure [18].
The 6MWT has been used as a parameter of physical
function and to correlate the capacity to undertake daily
activities [10,19,20]. Several authors [2,11,20–23] have
shown that the 6MWT is of great prognostic value in PH.
Although the three groups of lung function severity had a
similar performance in terms of distance walked, the groups
showed a significant increase of the PASP, according to
declining pulmonary function, and a significant increase in
the degree of desaturation during the 6MWT (Table 4). Our
findings are consistent with a previous report by Chetta et al.
[24] who demonstrated that the walk distance covered by
young adults with CF and ventilatory impairment was the
same as that covered by an age- and sex-matched controlgroup. It is therefore unlikely that peripheral oxygen delivery
was limiting in these patients. Maximum exercise capacity in
patients with CF depends on the severity of the impairment
in lung function and on the severity of the oxygen
desaturation [25,26]. However, 6MWT can be considered
as an endurance, submaximal exercise test, since it demands
the ability to sustain the exercise, rather than the capacity for
maximum exercise. Generally more vigorous exercise causes
greater desaturation than the exercise in 6MWT.
Both intermittent and sustained hypoxemia have been
implicated in the pathogenesis of PH in animal models
[27,28] and in human studies [2]. In our study, the PASP was
significantly correlated with SpO2 at rest and SpO2 during
6MWT. Furthermore, the regression analysis showed that
SpO2 at rest was predictive of elevated PASP, independent of
other variables. One of the most surprising findings in our
study was the large number of subjects with resting
saturations greater than or equal to 95% with elevated
PASP. It seems difficult to explain the raised PASP on the
basis of exercise desaturation. Chronic hypoxia is hard to
accept given that the lowest resting saturation was 92% and
only 2 patients were below 94%. Support for this finding
comes from studies in CF and stable lung disease [2,5]. It
was demonstrated that subclinical PH develops in a
substantial proportion of patients with CF and stable lung
disease and that it correlates with the frequency and severity
of episodes of arterial oxygen desaturation and with FEV1. A
potential relationship linking inflammation at the end of
respiratory exacerbation and PH was suggested [5].
Moreover, some CF patients may have excessive oxygen
desaturation during sleep, which may exert a cumulative
effect leading to PH [2].
PASP was significantly correlated with declining pulmo-
nary function (FEV1 and FVC) (Table 2). Pulmonary arterial
hypertension (PASP≥35 mm Hg) was found in 10 of 14
subjects (71%) with severe lung disease, in 10 of 12 subjects
(83%) with moderate lung disease and in 3 of 13 subjects
(23%) with mild lung disease without clinical signs of cor
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population of adult patients (N18 years old) with CF and
severe lung disease have PH without clinical signs of cor
pulmonale. Patients with better pulmonary function
(FEV1N40% predicted) found a higher incidence of
pulmonary hypertension.
In this study, we saw a significant difference in clinical
score of patients with PASP ≥35 mm Hg and patients with
normal PASP ( p=0.001). The clinical score was also
moderately correlated with the values of PASP and RVD.
Moderate correlation between the chest radiograph scores
and the PASP was also demonstrated.
In our study the mean age of diagnosis was 11.4 years old,
which surely must be late. This may have resulted in more
pulmonary vascular changes than would be suggested from
spirometric values. However, several limitations of using age
of diagnosis as a discriminate variable should be acknowl-
edged. In addition to differences in phenotype, delay in
diagnosismay be influenced by a variety of nonclinical factors,
such as access to and quality of health care, and implemen-
tation of newborn screening [29]. Although newborn
screening is too recent a development to have affected our
study population, in the future, newborn screening may
decrease the proportion of individuals diagnosed at later ages.
Moreover, it was widely assumed that much of the variability
in disease phenotype would be explained by difference in gene
mutations [30]. Additional study analyzing pulmonary
hypertension and genotype would clarify this question.
4.1. Implications of findings
The PASP was demonstrated to have association with
several variables such as SpO2 at rest, SpO2 at the end of the
6MWT, clinical score, chest radiograph scores, FEV1, and
FVC. Among these variables, however, only SpO2 at rest
was the best predictor of PASP. But there are many patients
with a normal resting saturation and an elevated PASP. It
may thus be useful to monitor PASP in CF patients with
chronic lung disease, despite normal resting oxygen
saturation. Otherwise, the 6MWT could contribute to
unmasking more advanced pulmonary vascular disease.
4.2. Limitations of study
The present study has several limitations. Studies in
patients with cardiac disease have revealed a significant
statistical correlation between PASP estimated by Doppler
echocardiography and that measured by right heart cathe-
terization [5,31,32]. However, in patients with chronic
pulmonary disease, Doppler echocardiography has been
reported to perform variably in the assessment of PASP.
Despite a close correlation between Doppler echocardiogra-
phy estimated and directly measured PASP, several studies
have revealed that such estimations were possible in only a
minority of patients with chronic pulmonary disease. If
Doppler echocardiography were to consistently overestimateor underestimate PASP by a constant value, correlation
would be high, but the accuracy of the estimation would be
dictated by the magnitude of the discrepancy. Despite a
statistically significant correlation with directly measured
values, estimation of PASP by echocardiography is
frequently inaccurate in patients with advanced lung
disease and leads to considerable overdiagnosis of PH
[32,33].
The technique employed to estimate PASP by echocar-
diography involves calculation of the trans-tricuspid gradient
from measuring the peak velocity of the tricuspid regurgi-
tation jet using the modified Bernoulli equation [16]. Right
ventricular pressure and, indirectly, PASP are then deter-
mined by adding an estimated right atrial pressure to
calculated trans-tricuspid gradient [16]. The success and
accuracy of this technique are dependent on the ability to
identify and precisely measure the velocity of the tricuspid
regurgitant jet and, therefore, are influenced by factors
altering the position of the heart in relationship to the
Doppler echocardiography probe such as obesity, thorax
deformities, and lung hyperinflation [34]. In our study, the
tricuspid regurgitation gradient could not be determined in
three patients and in consequence the PASP could not be
estimated. These patients were analyzed in the group with
normal PASP. It was not possible to measure the right
ventricular outflow tract flow acceleration time in one
patient. Furthermore, the intraobserver and interobserver
variability and limitations in the estimation of PASP can
also impact upon the accuracy of this technique [34]. In
the current study, one experienced cardiologist performed
all the analyses, so that it is difficult to assess whether
there was any bias in the estimates, and, if so, in which
direction.
In conclusion, we demonstrated that the PASP was not
significantly correlated with the distance walked during the
6MWT in patients with CF. The PASP was strongly
correlated with oxygen status at rest. The SpO2 at rest was
the best predictor of PASP. Also, PASP was strongly
correlated with Shwachman–Kulczycki score, FEV1, and
FVC in this population.
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